Macquarie raised target for Cipla stock to INR 1,730.00

Published on 10/12/2026 at 09:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cipla posted INR 7.89 billion net income in first-quarter 2027, down 39.00 percent year over year. Results on October 27, 2026 will test Cipla stock.

Key points in brief

Macquarie raised its Cipla target from INR 1,675.00 to INR 1,730.00 on October 7, 2026.
Cipla reported INR 7.89 billion net income in the first quarter of fiscal 2027, down 39.00 percent year over year.
The company is scheduled to announce results for the quarter and half-year ended September 30, 2026, on October 27, 2026.
Cipla had a market capitalization of INR 1.1 trillion as of October 12, 2026.

Cipla, INE059A01026, Illustration mit AI erstellt.

Macquarie raised its target for Cipla stock from INR 1,675.00 to INR 1,730.00 on October 7, 2026, according to Univest. The revision puts margin recovery ahead of the next results as the central test for the pharmaceutical company.

Three events shape the setup

On July 22, 2026, Cipla reported first-quarter fiscal 2027 revenue of INR 71.19 billion, up 2.00 percent year over year, while net income fell 39.00 percent to INR 7.89 billion, according to Investing.com.

On September 3, 2026, Cipla disclosed an exclusive licensing agreement with SBP Group for a potential HER2 bispecific antibody-drug conjugate, as listed in the company announcement record on The Economic Times. The September development adds a pipeline consideration to the earnings debate.

Macquarie's October 7 target stands INR 33.00 above the previous INR 1,675.00 target, a 3.00 percent increase calculated from the former target. That change contrasts with the first-quarter net income decline and makes the upcoming margin figures the more important confirmation point.

What will the results mean for margins?

Cipla's first-quarter EBITDA margin was 16.70 percent, against fiscal 2027 guidance of 18.50 percent to 20.00 percent, according to Investing.com. The 1.80 percentage-point gap to the lower end of guidance gives the next report a clear numerical benchmark.

Two dates define the next test

Cipla's board is scheduled to consider unaudited results for the quarter and half-year ended September 30, 2026, on October 27, 2026, according to The Economic Times. The trading window is scheduled to remain closed through October 29, 2026, with the same company announcement providing the date.

Market value and company profile

Cipla's market capitalization stood at INR 1.1 trillion as of October 12, 2026. The company is classified in the healthcare sector and pharmaceutical industry, and its Indian operations remain the key counterweight to pressure in North America.